TFS HealthScience, a contract research organization, announced the strategic acquisition of Appletree CI Group to enhance the company’s expertise in the complex fields of ophthalmology, dermatology, medical devices, and pediatric studies, simultaneously expanding geographic reach for clients.
The terms of the acquisition were not disclosed
Appletree CI Group was founded in 2013 following the merger of Clinical Investigations and Appletree. The company focuses on five primary business areas; in addition to ophthalmology and medical devices, they have expertise in dermatology, pediatric trials, and regulatory affairs.
Commenting on the acquisition news, CEO of TFS HealthScience, Bassem Saleh, said: “This acquisition, and others in the pipeline, are a clear indicator of the growth and success of TFS. The partnership with Appletree will have a measurable impact on better treatments for patients and company growth, establishing a new presence in Switzerland and additional presence in Poland, Belgium, Hungary, and the U.K.”
“We are thrilled to be joining the TFS HealthScience family,” said President and CEO of Appletree, Georg Mathis. “As one of the primary clinical service providers in Europe with in-depth knowledge of the complex medical devices and ophthalmology industry, we are prepared to exceed the expectations of our clients and patients.”
The two companies will now offer clients complimentary and expanded service offerings, including a specialized therapeutic focus in ophthalmology with an increased global footprint.
According to our M&A database, more than 3,000+ healthcare technology companies have been acquired to date. Recently, RealTime Software Solutions, a provider of cloud-based software solutions for the clinical research industry, announced the acquisition of Complion, a provider of cloud-based regulatory solutions for clinical trial sites, sponsors, and contract research organizations.
Click here to read more about the latest digital health M&A news…
